Plasmacytoid Dendritic Cells: Bring a Glimmer of Hope for Patients with Lymphangioleiomyomatosis.
作者信息
Du Heng, Liu Heng-Jia
机构信息
Division of Pulmonary and Critical Care Medicine Brigham and Women's Hospital Boston, Massachusetts.
Centre for Infection Immunity and Cancer Zhejiang University-University of Edinburgh Institute Haining, Zhejiang, China.
出版信息
Am J Respir Cell Mol Biol. 2024 Nov;71(5):503-504. doi: 10.1165/rcmb.2024-0266ED.
Abstract
摘要
相似文献
1
Plasmacytoid Dendritic Cells: Bring a Glimmer of Hope for Patients with Lymphangioleiomyomatosis.浆细胞样树突状细胞：为淋巴管平滑肌瘤病患者带来一线希望。
Am J Respir Cell Mol Biol. 2024 Nov;71(5):503-504. doi: 10.1165/rcmb.2024-0266ED.
2
Plasmacytoid Dendritic Cells Mediate CpG-ODN-induced Increase in Survival in a Mouse Model of Lymphangioleiomyomatosis.浆细胞样树突状细胞介导 CpG-ODN 诱导的淋巴管肌瘤病小鼠模型中存活率的增加。
Am J Respir Cell Mol Biol. 2024 Nov;71(5):519-533. doi: 10.1165/rcmb.2023-0410OC.
3
Plasmacytoid dendritic cells and memory T cells infiltrate true sequestrations stronger than subligamentous sequestrations: evidence from flow cytometric analysis of disc infiltrates.浆细胞样树突状细胞和记忆T细胞浸润真正的骨赘比韧带下骨赘更明显：来自椎间盘浸润流式细胞术分析的证据。
Eur Spine J. 2016 May;25(5):1417-1427. doi: 10.1007/s00586-015-4325-z. Epub 2016 Feb 23.
4
Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases.浆细胞样树突状细胞：一种在炎症性皮肤病中具有独特作用的新型皮肤树突状细胞亚群。
J Invest Dermatol. 2002 Nov;119(5):1096-102. doi: 10.1046/j.1523-1747.2002.19515.x.
5
Clinical Characteristics and Diagnosis of Acute Myeloid Leukemia with CD56-Blastic Plasmacytoid Dendritic Cell Neoplasm.伴有 CD56 阳性原始浆细胞样树突状细胞肿瘤的急性髓系白血病的临床特征和诊断。
Clin Lab. 2023 Jun 1;69(6). doi: 10.7754/Clin.Lab.2022.220929.
6
In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.浆细胞样树突状细胞肿瘤对靶向白细胞介素-3受体的生物制剂SL-401的体内和体外敏感性
Haematologica. 2015 Feb;100(2):223-30. doi: 10.3324/haematol.2014.111740. Epub 2014 Nov 7.
7
Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm.硼替佐米作为治疗原始浆细胞样树突细胞肿瘤的新方法。
Haematologica. 2017 Nov;102(11):1861-1868. doi: 10.3324/haematol.2017.169326. Epub 2017 Aug 10.
8
T Lymphoblastic Lymphoma Hiding in Mature Plasmacytoid Dendritic Cell Proliferation: A Case Report and Literature Review.隐匿于成熟浆细胞样树突状细胞增殖中的T淋巴母细胞淋巴瘤：一例报告及文献复习
Diagnostics (Basel). 2023 Oct 19;13(20):3248. doi: 10.3390/diagnostics13203248.
9
The expression of transmembrane and soluble CXCL16 and the relation with interferon-alpha secretion in patients with Behçet's disease.Behçet 病患者跨膜和可溶性 CXCL16 的表达及其与干扰素-α分泌的关系。
Clin Exp Rheumatol. 2013 May-Jun;31(3 Suppl 77):84-7. Epub 2013 Sep 9.
10
Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia.浆细胞样树突状细胞分化缺失对急性髓系白血病诱导后可测量残留病高度预测，并与不良预后相关。
Haematologica. 2019 Jul;104(7):1378-1387. doi: 10.3324/haematol.2018.203018. Epub 2018 Dec 6.
本文引用的文献
1
Plasmacytoid Dendritic Cells Mediate CpG-ODN-induced Increase in Survival in a Mouse Model of Lymphangioleiomyomatosis.浆细胞样树突状细胞介导 CpG-ODN 诱导的淋巴管肌瘤病小鼠模型中存活率的增加。
Am J Respir Cell Mol Biol. 2024 Nov;71(5):519-533. doi: 10.1165/rcmb.2023-0410OC.
2
Bi-steric mTORC1 inhibitors induce apoptotic cell death in tumor models with hyperactivated mTORC1.双位体型 mTORC1 抑制剂在 mTORC1 过度激活的肿瘤模型中诱导细胞凋亡。
J Clin Invest. 2023 Nov 1;133(21):e167861. doi: 10.1172/JCI167861.
3
mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion.mTORC1 上调 B7-H3/CD276 以抑制抗肿瘤 T 细胞并驱动肿瘤免疫逃逸。
Nat Commun. 2023 Mar 3;14(1):1214. doi: 10.1038/s41467-023-36881-7.
4
Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma.CpG-A Toll 样受体 9 激动剂 Vidutolimod 克服转移性黑色素瘤患者的 PD-1 阻断耐药性。
Cancer Discov. 2021 Dec 1;11(12):2998-3007. doi: 10.1158/2159-8290.CD-21-0425.
5
Discrepant antitumor efficacies of three CpG oligodeoxynucleotide classes in monotherapy and co-therapy with PD-1 blockade.三种 CpG 寡脱氧核苷酸类药物在单药治疗和联合 PD-1 阻断治疗中的抗肿瘤疗效差异。
Pharmacol Res. 2020 Nov;161:105293. doi: 10.1016/j.phrs.2020.105293. Epub 2020 Nov 8.
6
Adoptive T-Cell Transfer to Treat Lymphangioleiomyomatosis.采用过继性 T 细胞转移治疗淋巴管平滑肌瘤病。
Am J Respir Cell Mol Biol. 2020 Jun;62(6):793-804. doi: 10.1165/rcmb.2019-0117OC.
7
Plasmacytoid Dendritic Cells: Development, Regulation, and Function.浆细胞样树突状细胞：发育、调控和功能。
Immunity. 2019 Jan 15;50(1):37-50. doi: 10.1016/j.immuni.2018.12.027.
8
A multiprotein supercomplex controlling oncogenic signalling in lymphoma.一种控制淋巴瘤致癌信号的多蛋白超级复合物。
Nature. 2018 Aug;560(7718):387-391. doi: 10.1038/s41586-018-0290-0. Epub 2018 Jun 20.
9
TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.TSC2 缺陷型肿瘤有 T 细胞耗竭的证据，并对抗 PD-1/抗 CTLA-4 免疫疗法有反应。
JCI Insight. 2018 Apr 19;3(8). doi: 10.1172/jci.insight.98674.
10
Lymphangioleiomyomatosis: A Monogenic Model of Malignancy.淋巴管平滑肌瘤病：一种恶性肿瘤的单基因模型。
Annu Rev Med. 2017 Jan 14;68:69-83. doi: 10.1146/annurev-med-050715-104245.
Zotero 插件